Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 43-51

  Price, Matthew J ^b   Barker, Colin M ^a  

^a MEMORIAL HERMANN HOSPITAL   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

clopidogrel; P2Y12receptor; platelet; platelet function testing; prasugrel; stent; thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; BLEEDING; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; HEART INFARCTION; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; MULTIPLE ELECTRODE THROMBOCYTE AGGREGOMETRY; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PREDICTIVE VALUE; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; STENT THROMBOSIS; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION TESTING;

CORONARY VESSELS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2Y12;

EID: 79951789751     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.1     Document Type: Review

References (40)

1. Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/ non ST-elevation myocardial infarction) Circulation 116(7), e148-e304 (2007).
2. Price MJ: The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv. 3(3), 277-283; discussion 283 (2010).
3. Shuldiner AR, OConnell JR, Bliden KP et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
4. Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
5. Wiviott SD, Braunwald E, McCabe CH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007). (Pubitemid 350106708)
6. Bonello L, Tantry US, Marcucci R et al.: Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919-933 (2010).
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007). (Pubitemid 46517957)
8. Paniccia R, Antonucci E, Gori AM et al.: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J. Thromb. Haemost. 5, 1839-1847 (2007). (Pubitemid 47288940)
9. Buonamici P, Marcucci R, Migliorini A et al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312-2317 (2007). (Pubitemid 46891710)
10. Price MJ: Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119(19), 2625-2632 (2009).
11. Price MJ, Endemann S, Gollapudi RR et al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29(8), 992-1000 (2008). (Pubitemid 351844676)
12. Patti G, Nusca A, Mangiacapra F, Gatto L, Dambrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty- Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52(14), 1128-1133 (2008).
13. Migliorini A, Valenti R, Marcucci R et al.: High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120(22), 2214-2221 (2009).
14. Mangiacapra F, Barbato E, Patti G et al.: Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. Interv. 3(3), 318-323 (2010).
15. Breet NJ, Van Werkum JW, Bouman HJ et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762 (2010).
16. Campo G, Fileti L, De Cesare N et al.: Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/ or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56(18), 1447-1455 (2010).
17. Brar S, Patti G, Price MJ, Marcucci R, Cuisset T, Dangas G: Impact of platelet reactivity on clinical outcomes: a patient level meta-analysis. J. Am. Coll. Cardiol. 55, A179 (2010).
18. Price MJ: Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. In: American Heart Association Scientific Sessions. Chicago, IL, USA, 13-17 November 2010.
19. Kleiman NS: Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel? J. Am. Coll. Cardiol. 51(14), 1412-1414 (2008).
20. Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008). (Pubitemid 351447314)
21. Bonello L, Camoin-Jau L, Armero S et al.: Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103(1), 5-10 (2009).
22. Sibbing D, Braun S, Morath T et al.: Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849-856 (2009).
23. Sibbing D, Schulz S, Braun S et al.: Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8(2), 250-256 (2010).
24. Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A: Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J. Am. Coll. Cardiol. 56(4), 317-318 (2010).
25. Van Werkum JW, Kleibeuker M, Postma S et al.: A comparison between the PlateletWorks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int. J. Cardiol. 140(1), 123-126 (2010).
26. Hochholzer W, Trenk D, Bestehorn HP et al.: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742-1750 (2006). (Pubitemid 44648629)
27. Marcucci R, Gori AM, Paniccia R et al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted byresidual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237-242 (2009).
28. Gurbel PA, Tantry US: Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc. Interv. 3(10), 1008-1010 (2010).
29. Gurbel PA, Bliden KP, Butler K et al.: Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121(10), 1188-1199 (2010).
30. Jernberg T, Payne CD, Winters KJ et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(10), 1166-1173 (2006).
31. Jeong YH, Lee SW, Choi BR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53(13), 1101-1109 (2009).
32. Valgimigli M, Campo G, De Cesare N et al.: Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119(25), 3215-3222 (2009).
33. Price MJ, Berger PB, Angiolillo DJ et al.: Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am. Heart J. 157(5), 818-824 (2009).
34. Holmes DR, Dehmer GJ, Kaul S, Leifer D, OGara PT, Stein CM: ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122(5), 537-557 (2010).
35. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ: Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. J. Am. Coll. Cardiol. Interv. 3(10), 1001-1007 (2010).
36. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) http://clinicaltrials.gov/ct2/show/ NCT00910299
37. Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC) http:// clinicaltrials.gov/ct2/show/NCT00827 411?term=NCT00827411&rank=1
38. Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition (DANTE) http://clinicaltrials.gov/ct2/show/ NCT00774475?term= NCT00774475&recr= Open&rank=1
39. GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact on Thrombosis and Safety http://clinicaltrials.gov/ct2/show/ NCT00645918
40. Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI) http://clinicaltrials.gov/ct2/show/ NCT01177592?term=NCT01177592&ra nk=1